- Jim Minow, Executive Director of Cure JM
- Andrew Heaton, PhD, Chief Science Officer
- Shannon Malloy, Director of Development and Family Engagement
Research Grants: New Grantees and Exciting Updates From Existing Grant Recipients This year saw a very strong field of grant applications across a variety of
Hear directly from the researchers behind two exciting new treatments for juvenile myositis. Learn details of the new treatments and what these drugs could mean for you and your child with JM.
Juvenile myositis, including juvenile dermatomyositis and juvenile polymyositis, is a group of rare and life-threatening autoimmune diseases, in which the body’s immune system attacks its own cells and tissues.
Membership is free and we’ll connect you with a network of support, encouragement, and resources.